Abstract:Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, with a five-year survival rate only increasing from 6% to 12% in the last decade, indicating an urgent need for new therapeutic approaches. In recent years, immunotherapies like chimeric antigen receptor (CAR)-T cell therapy, have demonstrated promising therapeutic results in treating several hematological malignancies. However, the success has been limited in treating solid tumors, especially for PDAC. Factors contributing to this poor response include poor immunogenicity, highly heterogeneous and robust fibrotic and immunosuppressive tumor microenvironments (TMEs). Here, we used state-of-the-art imaging coupled with quantitative analysis to study dynamic T cell migration behavior in organotypic pancreatic tumor slices harvested from genetically engineered KPC mice. Our data showed that T cell speed and overall motility are both significantly lower in stroma-rich region PDA regions than observations in carcinoma cell-rich regions, where collagen fibers are loosely connected. Next, we utilized stroma-targeted approaches to deplete collagen and hyaluronan, the most abundant ECM components in the TME, to remove the biophysical barriers for effective immune therapy. Indeed, preliminary data demonstrated improved T cell infiltration and migration in the tumor slices in the STT-treated groups compared to the control groups. The observation is also confirmed with a therapeutic cell line generated with mesothelin-specific T cell receptors. Furthermore, we utilized genome engineering to generate CD8+ T cells that more effectively migrate in fibrous TMEs. Time-lapse imaging of the engineered T cells shows an increased 3D migration compared to control groups. Taken together, our data suggest that engineered T cell approaches in combination with stromal targeted therapies to diminish stromal ECM content have the potential to improve immunotherapy by allowing effector T cells to sample the tumor volume more effectively. Citation Format: Hongrong Zhang, Guhan Qian, Zhongming Chen, Branden Moriarity, Ingunn Stromnes, David Odde, Paolo Provenzano. Enhancing T cell infiltration and migration in the pancreatic tumor microenvironment [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr C046.

Immunosuppressive microenvironment improvement and treatment of aggressive malignancy pancreatic ductal adenocarcinoma based on local administration of injectable hydrogel

Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects

Injectable Hybrid Hydrogels Enable Enhanced Combination Chemotherapy and Roused Anti-Tumor Immunity in the Synergistic Treatment of Pancreatic Ductal Adenocarcinoma

In Situ Formed ROS‐Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy Against Pancreatic Ductal Adenocarcinoma

Immunosuppression, Immune Escape, and Immunotherapy in Pancreatic Cancer: Focused on the Tumor Microenvironment

Engineering ROS‐Responsive Bioscaffolds for Disrupting Myeloid Cell‐Driven Immunosuppressive Niche to Enhance PD‐L1 Blockade‐Based Postablative Immunotherapy

Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment

Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

[Advances in Immunotherapy of Pancreatic Ductal Adenocarcinoma].

Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy

Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment

Immunotherapy for pancreatic ductal adenocarcinoma: Challenges and opportunities

Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective

Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy.

Abstract C046: Enhancing T cell infiltration and migration in the pancreatic tumor microenvironment

Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief

Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy

Pyroptosis Remodeling Tumor Microenvironment to Enhance Pancreatic Cancer Immunotherapy Driven by Membrane Anchoring Photosensitizer